Washington Trust Bank Has Lifted Its Iff (IFF) Position; 8 Analysts Covering Charles River Laboratories International, Inc. (CRL)

January 17, 2018 - By Jerrie Dane

Among 16 analysts covering Charles River Laboratories (NYSE:CRL), 8 have Buy rating, 1 Sell and 7 Hold. Therefore 50% are positive. Charles River Laboratories had 39 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) has “Hold” rating given on Friday, July 31 by Deutsche Bank. Goldman Sachs upgraded Charles River Laboratories International, Inc. (NYSE:CRL) on Friday, December 16 to “Neutral” rating. Credit Suisse reinitiated the stock with “Neutral” rating in Friday, August 14 report. Citigroup maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Thursday, August 4 with “Neutral” rating. Robert W. Baird maintained the stock with “Buy” rating in Thursday, August 31 report. Jefferies maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Tuesday, June 13 with “Buy” rating. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) has “Outperform” rating given on Thursday, January 7 by Wells Fargo. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) has “Buy” rating given on Tuesday, April 26 by Gabelli. The rating was maintained by KeyBanc Capital Markets with “Hold” on Monday, November 13. The rating was upgraded by Barclays Capital to “Equal Weight” on Wednesday, November 30. See Charles River Laboratories International, Inc. (NYSE:CRL) latest ratings:

13/12/2017 Broker: Argus Research Rating: Buy New Target: $120 Initiates Coverage On
16/11/2017 Broker: SunTrust Rating: Buy New Target: $113.0 Maintain
13/11/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
13/11/2017 Broker: Robert W. Baird Rating: Buy New Target: $117.0 Maintain
13/11/2017 Broker: Jefferies Rating: Buy Old Target: $135 New Target: $124 Maintain
10/11/2017 Broker: Bank of America Rating: Buy Old Target: $117 New Target: $115 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $110.0 Maintain
16/10/2017 Broker: Credit Suisse Rating: Hold New Target: $112.0 Maintain
12/10/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
09/10/2017 Broker: Jefferies Rating: Buy Upgrade

Washington Trust Bank increased Iff (IFF) stake by 1000% reported in 2017Q3 SEC filing. Washington Trust Bank acquired 3,000 shares as Iff (IFF)’s stock rose 10.17%. The Washington Trust Bank holds 3,300 shares with $472,000 value, up from 300 last quarter. Iff now has $12.05 billion valuation. The stock decreased 0.75% or $1.16 during the last trading session, reaching $152.54. About 252,049 shares traded. International Flavors & Fragrances Inc. (NYSE:IFF) has risen 5.32% since January 17, 2017 and is uptrending. It has underperformed by 11.38% the S&P500.

Since August 1, 2017, it had 11 insider buys, and 4 insider sales for $76.69 million activity. Chwat Anne also sold $411,660 worth of International Flavors & Fragrances Inc. (NYSE:IFF) on Tuesday, August 15. Another trade for 59,190 shares valued at $7.97 million was bought by Winder Investment Pte Ltd. MIRZAYANTZ NICOLAS had sold 1,233 shares worth $169,192. $40,308 worth of International Flavors & Fragrances Inc. (NYSE:IFF) was sold by Fortanet Francisco.

Investors sentiment increased to 1.08 in 2017 Q3. Its up 0.29, from 0.79 in 2017Q2. It improved, as 21 investors sold IFF shares while 144 reduced holdings. 53 funds opened positions while 126 raised stakes. 53.47 million shares or 1.08% less from 54.06 million shares in 2017Q2 were reported. Citadel Advisors Ltd Liability Co reported 0.07% stake. Moreover, Winslow Evans & Crocker Inc has 0% invested in International Flavors & Fragrances Inc. (NYSE:IFF) for 106 shares. State Common Retirement Fund invested in 0.05% or 283,540 shares. Covington Cap Management holds 34,014 shares. Westpac Banking holds 5,176 shares or 0.02% of its portfolio. Campbell Newman Asset Mgmt accumulated 250,000 shares or 6.39% of the stock. Marietta Prns Ltd Llc owns 3,000 shares. Creative Planning stated it has 5,884 shares or 0% of all its holdings. & Mngmt Company reported 0.05% of its portfolio in International Flavors & Fragrances Inc. (NYSE:IFF). Lord Abbett And Limited Liability Company has invested 0.05% in International Flavors & Fragrances Inc. (NYSE:IFF). Front Barnett Associates Ltd has 122,623 shares for 3.08% of their portfolio. Trillium Asset Mgmt Ltd Co holds 71,253 shares. Barclays Public Limited Com holds 0% in International Flavors & Fragrances Inc. (NYSE:IFF) or 25,011 shares. Sun Life invested in 582 shares. Boston Family Office has invested 0.24% of its portfolio in International Flavors & Fragrances Inc. (NYSE:IFF).

Among 16 analysts covering Internationa Flavors & Fragrances (NYSE:IFF), 7 have Buy rating, 1 Sell and 8 Hold. Therefore 44% are positive. Internationa Flavors & Fragrances has $166 highest and $103 lowest target. $148.86’s average target is -2.41% below currents $152.54 stock price. Internationa Flavors & Fragrances had 31 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Hold” rating by Stifel Nicolaus given on Monday, September 18. The firm has “Overweight” rating by KeyBanc Capital Markets given on Monday, October 16. Barclays Capital maintained the shares of IFF in report on Monday, May 15 with “Sell” rating. Deutsche Bank maintained the shares of IFF in report on Wednesday, May 11 with “Hold” rating. On Thursday, October 1 the stock rating was upgraded by Edward Jones to “Buy”. As per Thursday, February 23, the company rating was upgraded by UBS. Goldman Sachs initiated the stock with “Neutral” rating in Monday, November 21 report. The firm has “Hold” rating by Stifel Nicolaus given on Monday, January 25. The rating was maintained by Deutsche Bank with “Hold” on Thursday, August 10. As per Tuesday, August 16, the company rating was maintained by Argus Research.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. The company has market cap of $5.01 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It has a 25.82 P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

The stock increased 0.40% or $0.42 during the last trading session, reaching $105.76. About 423,214 shares traded or 10.10% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 7.06% since January 17, 2017 and is uptrending. It has underperformed by 9.64% the S&P500.

Investors sentiment increased to 1.46 in 2017 Q3. Its up 0.09, from 1.37 in 2017Q2. It increased, as 18 investors sold Charles River Laboratories International, Inc. shares while 92 reduced holdings. 55 funds opened positions while 106 raised stakes. 44.95 million shares or 0.15% less from 45.02 million shares in 2017Q2 were reported. Mackenzie holds 0.54% in Charles River Laboratories International, Inc. (NYSE:CRL) or 928,796 shares. King Luther Capital Mgmt accumulated 90,813 shares. Moreover, Arrowstreet Limited Partnership has 0.05% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Clinton Grp invested 0.06% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Teacher Retirement Sys Of Texas has 0% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 3,921 shares. Stifel Fin Corp invested in 0% or 2,183 shares. State Of Tennessee Treasury Department holds 40,000 shares. Asset Mgmt owns 2,814 shares or 0.01% of their US portfolio. Weaver C Barksdale & Associate reported 92 shares. Prelude Capital Management Lc holds 0.03% or 3,039 shares in its portfolio. Nuveen Asset Mgmt Ltd Llc, a Illinois-based fund reported 4,788 shares. Meeder Asset Mgmt holds 0.07% or 5,750 shares. Castleark Management Ltd Limited Liability Company reported 5,010 shares. Primecap Mgmt Communication Ca reported 0.04% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Ig Inv Mngmt Limited holds 0% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) for 5,778 shares.